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A bs tr ac t
Background
The clinically appropriate duration of thromboprophylaxis in hospitalized patients 
with acute medical illnesses is unknown. In this multicenter, randomized, double-
blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for 
an extended period, as compared with subcutaneous enoxaparin administered for a 
standard period, followed by placebo.
Methods
We randomly assigned patients 40 years of age or older who were hospitalized for an 
acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 
10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 
10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary ef-
ficacy outcomes were the composite of asymptomatic proximal or symptomatic 
venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (supe-
riority test). The principal safety outcome was the composite of major or clinically 
relevant nonmajor bleeding.
Results
A total of 8101 patients underwent randomization. A primary efficacy outcome event 
occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients 
(2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% 
confidence interval [CI], 0.71 to 1.31; P = 0.003 for noninferiority) and in 131 of 
2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who 
received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 
0.96; P = 0.02). A principal safety outcome event occurred in 111 of 3997 patients 
(2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin 
group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the 
respective groups at day 35 (P<0.001).
Conclusions
In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for stan-
dard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk 
of venous thromboembolism. Rivaroxaban was associated with an increased risk of 
bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and 
Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.)
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Patients with active cancer, stroke, myocardial infarction, or acute exacerba-tions of a variety of medical conditions are 
at increased risk for venous thromboembolism.1 
Prolonged immobilization and risk factors such 
as an age older than 75 years, chronic heart fail-
ure, a history of venous thromboembolism, and 
obesity can increase this risk further.2,3
Randomized, controlled trials involving hospi-
talized patients at increased risk for venous throm-
boembolism have shown the benefits of adminis-
tering anticoagulant agents for up to 14 days,4-8 
and guidelines recommend the use of unfraction-
ated heparin, low-molecular-weight heparins, or 
fondaparinux in such patients.9 There is some 
evidence that the risk of venous thromboembo-
lism in acutely ill medical patients persists after 
hospital discharge10; however, no studies have 
supported the routine use of extended thrombo-
prophylaxis.11,12
Rivaroxaban is an oral, direct factor Xa in-
hibitor that is used for the prevention of venous 
thromboembolism after elective hip-replacement 
or knee-replacement surgery in adults. The Multi-
center, Randomized, Parallel Group Efficacy and 
Safety Study for the Prevention of Venous Throm-
boembolism in Hospitalized Acutely Ill Medical 
Patients Comparing Rivaroxaban with Enoxaparin 
(MAGELLAN) was designed to assess the effi-
cacy and safety of rivaroxaban administered for 
35 days, as compared with enoxaparin adminis-
tered for 10 days and followed by placebo, in a 
heterogeneous population of patients 40 years of 
age or older with reduced mobility and an acute 
medical illness requiring hospitalization.
Me thods
Study Oversight
MAGELLAN was a randomized, double-blind, ac-
tive-comparator–controlled, multinational clinical 
trial.13 The study was designed and supervised by 
the steering committee (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org) and was sponsored by Bayer 
HealthCare Pharmaceuticals and Janssen Research 
and Development. The members of the steering 
committee signed confidentiality agreements 
with the study sponsors. The data were collected 
and analyzed by the sponsors. All the authors 
had full access to the data and analyses and con-
tributed to the writing of the manuscript. Edito-
rial assistance was provided by Chameleon Com-
munications. The steering committee made the 
decision to submit the manuscript for publica-
tion. The academic authors vouch for the accu-
racy and completeness of the report and for the 
fidelity of the report to the trial protocol, which 
is available at NEJM.org.
The trial was conducted in accordance with the 
Declaration of Helsinki and local regulations. 
The protocol was approved by the relevant local 
institutional review boards and ethics commit-
tees, and written informed consent was obtained 
from each patient before any study-specific pro-
cedures were performed.
Patients, Treatments, and Follow-up
Patients were eligible for the study if they were 
40 years of age or older, had been hospitalized 
for a specified acute medical illness for less than 
72 hours before randomization, and had reduced 
mobility. Full inclusion and exclusion criteria are 
provided in Table S1 in the Supplementary Ap-
pendix. Randomization was performed in per-
muted blocks with the use of an interactive voice-
response system, with stratification according to 
center. Eligible patients were randomly assigned 
to receive subcutaneous enoxaparin, 40 mg once 
daily, for 10±4 days and oral placebo, once daily, 
for 35±4 days or to receive subcutaneous placebo, 
once daily, for 10±4 days and oral rivaroxaban, 
10 mg once daily, for 35±4 days.
The protocol called for ultrasonography to be 
performed in all patients for the detection of 
asymptomatic deep-vein thrombosis after the 
last dose of study medication or matching pla-
cebo was administered on day 10±4 and on day 
35±4, as described previously.13 During the follow-
up period, clinically suspected cases of deep-
vein thrombosis were confirmed with the use of 
ultrasonography or other vascular imaging tech-
niques, and clinically suspected pulmonary embo-
lism was confirmed with the use of thoracic spiral 
computed tomography, ventilation–perfusion lung 
scanning with chest radiography, or pulmonary 
angiography.
Outcome Measures
All outcomes were assessed by an independent, 
central adjudication committee whose members 
were unaware of the study assignments. There 
were two coprimary efficacy outcomes. The first 
was a composite of asymptomatic proximal deep-
vein thrombosis, symptomatic proximal or distal 
deep-vein thrombosis, symptomatic nonfatal pul-
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monary embolism, or death related to venous 
thromboembolism from day 1 to day 10 (day 10 
analysis). The second was this same composite 
outcome from day 1 to day 35 (day 35 analysis). 
The primary day 10 analysis was prespecified to 
be a noninferiority analysis, and the primary 
day 35 analysis was prespecified to be a superior-
ity analysis.
There were two major secondary efficacy out-
comes: a composite of asymptomatic proximal 
deep-vein thrombosis, symptomatic proximal or 
distal deep-vein thrombosis, symptomatic non-
fatal pulmonary embolism, or death from any 
cause (i.e., the primary outcome, with the com-
ponent of death related to venous thromboem-
bolism replaced by death from any cause), up to 
day 35; and a superiority analysis of the primary 
efficacy outcome up to day 10 in the modified 
intention-to-treat population. Other secondary 
efficacy outcomes included the incidence of 
symptomatic venous thromboembolism up to 
day 10 and the incidence up to day 35; the inci-
dence of each of the components of the two 
coprimary efficacy outcomes; and the incidence 
of the composite of cardiovascular death, acute 
myocardial infarction, or acute ischemic stroke up 
to day 10 and up to day 35.
The principal safety outcome was clinically 
relevant bleeding, which was a composite of 
major bleeding or clinically relevant nonmajor 
bleeding events observed no later than 2 days 
after administration of the last dose of double-
blind study medication. The definitions of major 
bleeding and clinically relevant nonmajor bleed-
ing are provided in Table S2 in the Supplementary 
Appendix. Overt bleeding episodes that did not 
meet the criteria for either of these outcomes, ad-
verse events that occurred during the treatment 
period, and abnormal laboratory results were also 
evaluated. The outcome of net clinical benefit or 
harm was assessed as the composite of the pri-
mary efficacy outcome or the principal safety 
outcome up to day 10 and up to day 35. 
Statistical Analysis
Details of the statistical analyses have been re-
ported previously.13 In brief, two populations were 
defined — a modified intention-to-treat popula-
tion and a per-protocol population — both for 
the noninferiority (day 10) efficacy analysis and 
for the superiority (day 35) efficacy analysis. For 
both efficacy analyses, patients were included in 
the modified intention-to-treat population if they 
met the study inclusion criteria, had received at 
least one dose of study medication, and had an 
adequate assessment of venous thromboembo-
lism. Patients were included in the per-protocol 
population if they met the criteria for inclusion in 
the modified intention-to-treat population, under-
went an adequate assessment of venous throm-
boembolism not later than 2 days after adminis-
tration of the last dose of study drug, and had no 
major protocol violations. Patients were included 
in the safety population if they had received at 
least one dose of study medication.
For both coprimary efficacy outcomes, the rela-
tive risk ratio of the incidence rates (rivaroxaban 
as compared with enoxaparin) was estimated on 
the basis of a Mantel–Haenszel model with strati-
fication according to geographic region. The per-
protocol population was the primary population 
for the noninferiority analysis (at day 10), and the 
modified intention-to-treat population was the 
primary population for the superiority analysis 
(at day 35). All statistical tests were one-sided, 
with a type I error rate of 2.5%, and two-sided 
95% confidence intervals were calculated.14
We estimated that with a sample of 2876 pa-
tients per group who could be evaluated for the 
coprimary efficacy outcomes, the study would 
have at least 90% power to determine both the 
noninferiority (for the day 10 analysis) and supe-
riority (for the day 35 analysis) of rivaroxaban as 
compared with enoxaparin. For the day 10 non-
inferiority analysis, the following assumptions 
were made: a 2.2% event rate in the enoxaparin 
group, a 1.4% event rate in the rivaroxaban group, 
and a relative risk reduction with rivaroxaban of 
at least 35%. The estimate of the sample size 
assumed a relative risk noninferiority margin of 
1.5. For the day 35 superiority analysis, the fol-
lowing assumptions were made: a 4.0% event 
rate in the enoxaparin group, a 2.4% event rate 
in the rivaroxaban group, and a relative risk re-
duction with rivaroxaban of at least 40%.
For the safety analysis, all statistical tests were 
two-sided, with a type I error rate of 5%. The 
outcomes of the composite of major bleeding or 
clinically relevant nonmajor bleeding and of ma-
jor bleeding alone were analyzed in the same way 
as were the coprimary efficacy outcomes. All 
other safety data were analyzed descriptively. In 
exploratory analyses, the incidence rates, as well 
as the relative risk and the corresponding non-
stratified asymptotic two-sided 95% confidence 
intervals, of the primary efficacy and principal 
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safety outcomes in each treatment group were 
reported in subgroups defined according to age, 
sex, and acute medical condition.
R esult s
Study Populations
From December 2007 through July 2010, a total of 
8428 patients were enrolled at 556 sites in 52 coun-
tries. Of these patients, 8101 underwent random-
ization: 4050 to the rivaroxaban group and 4051 to 
the enoxaparin group (Fig. 1). The baseline char-
acteristics of the patients, the incidences of acute 
medical conditions, and the risk factors for ve-
nous thromboembolism were well balanced be-
tween the two groups (Table 1). More than 30% 
of the patients overall had two or more acute 
medical conditions, and the median duration of 
hospitalization in both groups was 11 days.
The numbers of patients included in each 
analysis are shown in Figure 1. A total of 53 pa-
tients in the rivaroxaban group and 50 patients 
in the enoxaparin group did not receive the study 
medication and were excluded from the safety 
analyses. In the rivaroxaban group, an additional 
765 patients were excluded from the modified 
intention-to-treat analysis at day 10 and 1030 at 
day 35, with the lack of an adequate assessment 
of venous thromboembolism as the main reason 
for exclusion. In the enoxaparin group, an addi-
tional 730 patients were excluded from the 
modified intention-to-treat analysis at day 10 and 
944 at day 35. A comparison of the baseline char-
acteristics of patients who underwent venous 
ultrasonography at day 35 and those who did not 
is shown in Table S3 in the Supplementary Ap-
pendix. An additional 294 patients in the rivarox-
aban group and 278 in the enoxaparin group were 
excluded from the per-protocol analysis. The 
total numbers of patients included in each of the 
analysis populations are provided in Table S4 in 
the Supplementary Appendix.
Efficacy Outcomes
In the day 10 analysis of data from the per-proto-
col population, 78 of 2938 patients (2.7%) in the 
rivaroxaban group and 82 of 2993 patients (2.7%) 
in the enoxaparin group had a primary outcome 
event, with rivaroxaban meeting the prespecified 
criterion for noninferiority (relative risk with riva-
roxaban, 0.97; 95% confidence interval [CI], 0.71 
to 1.31; P = 0.003 for noninferiority) (Table 2). In 
the day 35 analysis of data from the modified 
intention-to-treat population, 131 of 2967 pa-
tients (4.4%) in the group that received extended-
duration rivaroxaban, as compared with 175 of 
3057 patients (5.7%) in the group that received 
enoxaparin followed by placebo, had a primary 
outcome event; thus, extended-duration rivaroxa-
ban met the conventional criterion for superiority 
(relative risk with rivaroxaban, 0.77; 95% CI, 0.62 
to 0.96; P = 0.02) (Table 2). Primary efficacy out-
come events between day 11 and day 35 occurred 
in 72 of 2934 patients (2.5%) who received rivarox-
aban and in 114 of 3017 patients (3.8%) who re-
ceived enoxaparin followed by placebo (relative 
risk with rivaroxaban, 0.65; 95% CI, 0.49 to 0.87; 
P = 0.004). There was no evidence of heterogene-
ity according to subgroup with respect to the pri-
mary outcome at day 35 (Fig. S1 in the Supple-
mentary Appendix).
With respect to the first major secondary ef-
ficacy outcome (the primary efficacy outcome up 
to day 35, with death related to venous thrombo-
embolism replaced by death from any cause), an 
event occurred in 266 of 3096 patients (8.6%) in 
the group that received extended-duration rivarox-
aban and in 293 of 3169 patients (9.2%) in the 
group that received enoxaparin followed by pla-
cebo (relative risk with rivaroxaban, 0.93; 95% 
CI, 0.80 to 1.09; P = 0.38) (Table 3). With respect 
to the second major secondary efficacy outcome 
(the primary efficacy outcome up to day 10 for a 
superiority analysis in the modified intention-to-
treat population), an event occurred in 98 of 
3232 patients (3.0%) in the rivaroxaban group 
and in 100 of 3271 patients (3.1%) in the enoxa-
parin group (relative risk with rivaroxaban, 0.99; 
95% CI, 0.75 to 1.30; P = 0.95). The incidences of 
symptomatic venous thromboembolism and of 
the composite of cardiovascular death, acute 
myocardial infarction, or acute ischemic stroke 
did not differ significantly between the two 
groups at day 10 or at day 35.
Safety Outcomes
Between day 1 and day 10, an episode of clini-
cally relevant bleeding occurred in 111 of 3997 
Figure 1 (facing page). Randomization, Treatment, 
and Inclusion in Analyses.
Some patients met more than one exclusion criterion. 
VTE denotes venous thromboembolism.
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Table 1. Baseline Characteristics of Patients Who Underwent Randomization.*
Characteristic Rivaroxaban (N = 4050) Enoxaparin (N = 4051)
Median age — yr 71.0 71.0
Male sex — no. (%) 2253 (55.6) 2136 (52.7)
Mean weight — kg 77.5 77.3
Mean body-mass index† 28.2 28.2
Median duration of hospitalization — days 11.0 11.0
Creatinine clearance — no. (%)‡
<30 ml/min 82 (2.0) 64 (1.6)
30 to <50 ml/min 788 (19.5) 807 (19.9)
50 to ≤80 ml/min 1500 (37.0) 1546 (38.2)
>80 ml/min 1582 (39.1) 1537 (37.9)
Race — no. (%)§
White 2784 (68.7) 2744 (67.7)
Asian 804 (19.9) 806 (19.9)
Other 280 (6.9) 290 (7.2)
Median d-dimer level — µg/ml¶ 0.94 0.95
Acute medical condition — no. (%)
Infectious disease 1854 (45.8) 1828 (45.1)
Heart failure 1308 (32.3) 1312 (32.4)
Respiratory insufficiency 1105 (27.3) 1163 (28.7)
Ischemic stroke 699 (17.3) 700 (17.3)
Active cancer 296 (7.3) 296 (7.3)
Inflammatory or rheumatic disease 152 (3.8) 151 (3.7)
Other 34 (0.8) 24 (0.6)
≥2 Medical conditions 1240 (30.6) 1270 (31.4)
Risk factor for VTE — no. (%)
Age ≥75 yr 1551 (38.3) 1565 (38.6)
History of heart failure‖ 1408 (34.8) 1382 (34.1)
History of cancer 700 (17.3) 678 (16.7)
Acute ischemic stroke with leg paresis 661 (16.3) 668 (16.5)
Chronic venous insufficiency 617 (15.2) 579 (14.3)
Body-mass index ≥35 612 (15.1) 618 (15.3)
Acute infectious disease 566 (14.0) 601 (14.8)
Severe varicosis 501 (12.4) 461 (11.4)
History of DVT or pulmonary embolism 202 (5.0) 179 (4.4)
Hormone-replacement therapy 48 (1.2) 50 (1.2)
Major surgery within the previous 6 to 12 wk 29 (0.7) 32 (0.8)
Hereditary or acquired thrombophilia 15 (0.4) 9 (0.2)
Serious trauma within the previous 6 to 12 wk 7 (0.2) 7 (0.2)
* There were no significant differences between the two groups in any of the baseline characteristics listed here. DVT de-
notes deep-vein thrombosis, and VTE venous thromboembolism.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Creatinine clearance levels were calculated with the use of the equation of Cockcroft and Gault. The values shown are 
day 1 levels.
§ Race was self-reported.
¶ The d-dimer level was calculated in the safety population (all patients who underwent randomization and received at 
least one dose of study medication), which included 7998 patients (3997 in the rivaroxaban group and 4001 in the 
enoxaparin group). The normal range is less than 0.5 µg per milliliter.
‖ Included are patients with a history of New York Heart Association heart failure class III or IV.
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patients (2.8%) who were receiving rivaroxaban 
as compared with 49 of 4001 patients (1.2%) who 
were receiving enoxaparin (relative risk, 2.3; 95% 
CI, 1.63 to 3.17; P<0.001), and fatal bleeding oc-
curred in 5 patients in the rivaroxaban group and 
in 1 patient in the enoxaparin group. Between 
day 1 and day 35, an episode of clinically relevant 
bleeding occurred in 164 of 3997 patients (4.1%) 
in the group that received extended-duration riva-
roxaban as compared with 67 of 4001 patients 
(1.7%) in the group that received enoxaparin fol-
lowed by placebo (relative risk, 2.5; 95% CI, 1.85 to 
3.25; P<0.001). There was no evidence of hetero-
geneity according to subgroup with respect to 
clinically relevant bleeding at day 35 (Fig. S2 in 
the Supplementary Appendix). Fatal bleeding oc-
curred in 7 patients in the group that received 
extended-duration rivaroxaban and in 1 patient in 
the group that received enoxaparin followed by 
placebo. The seven fatal bleeding events involved 
pulmonary bleeding (in 3 patients), intracranial 
bleeding (in 2 patients), and retroperitoneal and 
gastrointestinal bleeding (each in 1 patient). In 
the enoxaparin group there was one death due to 
tracheal bleeding.
The adverse-event profiles and the incidence of 
any cardiovascular event were similar up to day 
35 in the group that received extended-duration 
rivaroxaban and the group that received enoxa-
parin followed by placebo (Table 4). Over the 
total study period, alanine aminotransferase el-
evations greater than three times the upper 
limit of the normal range with a concurrent el-
evation in the bilirubin level that was greater 
than two times the upper limit of the normal 
range occurred in 7 of 3364 patients (0.2%) in 
the rivaroxaban group and 7 of 3382 patients 
(0.2%) in the enoxaparin group (measurements 
were not available for approximately 16% of the 
patients). The incidence of death from any cause 
over the entire study period was similar in the 
two groups.
Net Clinical Benefit or Harm
By day 10, an event of the primary efficacy out-
come or major or clinically relevant nonmajor 
bleeding (the measure of net clinical benefit or 
harm) had occurred in 216 of 3266 patients 
(6.6%) in the rivaroxaban group, as compared 
with 151 of 3291 patients (4.6%) in the enoxapa-
rin group (relative risk, 1.44; 95% CI, 1.18 to 
1.77; P<0.001) (Table 3). By day 35, an event of 
this composite outcome had occurred in 286 of 
3042 patients (9.4%) in the group that received 
extended-duration rivaroxaban, as compared with 
240 of 3082 patients (7.8%) in the group that re-
ceived enoxaparin followed by placebo (relative 
risk, 1.21; 95% CI, 1.03 to 1.43; P = 0.02) (Table 3).
Table 2. Rates of the Composite Primary Efficacy Outcome and Its Components.
Outcome Day 10 Day 35
Rivaroxaban
(N = 2938)
Enoxaparin 
(N = 2993)
Relative Risk
(95% CI)* P Value†
Rivaroxaban 
(N = 2967)
Enoxaparin– 
Placebo 
(N = 3057)
Relative Risk 
(95% CI)* P Value†
no. (%) no. (%)
Composite primary efficacy 
outcome
78 (2.7) 82 (2.7) 0.97 (0.71– 1.31) 0.003 131 (4.4) 175 (5.7) 0.77 (0.62– 0.96) 0.02
Asymptomatic proximal DVT 71 (2.4) 71 (2.4) — — 103 (3.5) 133 (4.4) — —
Symptomatic proximal or 
distal DVT
7 (0.2) 6 (0.2) — — 13 (0.4) 15 (0.5) — —
Symptomatic nonfatal  
pulmonary embolism
6 (0.2)   2 (<0.1) — — 10 (0.3) 14 (0.5) — —
VTE-related death 3 (0.1) 6 (0.2) — — 19 (0.6) 30 (1.0) — —
* Two-sided 95% confidence intervals (CI) for weighted relative risks were calculated with the use of asymptotic methods, with weights based 
on sample sizes per stratum of geographic region.
† The P values were calculated on the basis of the normal approximation. The P value for the day 10 analysis is a one-sided P value for nonin-
feriority, calculated in the per-protocol population; the P value for the day 35 analysis is a two-sided P value for superiority, calculated in the 
modified intention-to-treat population.
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Discussion
In MAGELLAN, we investigated the efficacy and 
safety of rivaroxaban for the prevention of venous 
thromboembolism in acutely ill hospitalized pa-
tients. The study included a population of pa-
tients that was heterogeneous with respect to the 
medical condition leading to hospitalization and 
the geographic origin and race of the patients.13 
We found that for the standard duration of ther-
apy (10±4 days), rivaroxaban was noninferior to 
enoxaparin. Rivaroxaban administered for an 
 extended duration (35±4 days) was superior to 
enoxaparin administered for the standard dura-
tion (10±4 days) followed by placebo.
The rate of clinically relevant bleeding (a com-
posite of major or nonmajor bleeding) was sig-
nificantly higher in the rivaroxaban group than 
in the enoxaparin group. The incidence of major 
bleeding events was also significantly higher in 
the rivaroxaban group than in the enoxaparin 
group, with the majority of events in both groups 
leading to a fall in the hemoglobin level of at 
least 2 g per deciliter or to the transfusion of at 
least 2 units of blood. A reduction in the rate of 
death related to venous thromboembolism and 
an increase in the rate of death related to bleed-
ing were seen with extended-duration rivaroxaban 
prophylaxis. However, there was no reduction 
with rivaroxaban in the rate of death from any 
cause, and the incidence was similar in the two 
groups — findings that were consistent with 
those in other studies.11,12 The prespecified anal-
ysis of net clinical benefit or harm did not show a 
benefit with rivaroxaban at either day 10 or day 35.
Factors that influence the risk of bleeding in 
acutely ill medical patients are not well defined. 
A recent study identified risk factors at admission 
that were associated with in-hospital bleeding in 
acutely ill medical patients; the risk factors in-
cluded active gastroduodenal ulcer, prior bleed-
ing, low platelet count, increasing age, hepatic 
Table 4. Safety Outcomes.*
Outcome
Rivaroxaban
(N = 3997)
Enoxaparin–
Placebo 
(N = 4001)
Relative Risk 
(95% CI) P Value
no. (%)
Clinically relevant bleeding: principal safety outcome at day 10 111 (2.8) 49 (1.2) 2.3 (1.63–3.17) <0.001
Any major bleeding 24 (0.6) 11 (0.3) 2.2 (1.07–4.45) 0.03
Major bleeding leading to fall in hemoglobin of ≥2 g/dl 17 (0.4) 7 (0.2) — —
Major bleeding leading to transfusion of ≥2 units of blood 15 (0.4) 5 (0.1) — —
Major bleeding at a critical site 5 (0.1) 1 (<0.1) — —
Fatal major bleeding 5 (0.1) 1 (<0.1) — —
Clinically relevant bleeding: principal safety outcome at day 35 164 (4.1) 67 (1.7) 2.5 (1.85– 3.25) <0.001
Any major bleeding 43 (1.1) 15 (0.4) 2.9 (1.60–5.15) <0.001
Major bleeding leading to fall in hemoglobin of ≥2 g/dl 31 (0.8) 10 (0.2) — —
Major bleeding leading to transfusion of ≥2 units of blood 24 (0.6) 8 (0.2) — —
Major bleeding at a critical site 9 (0.2) 4 (0.1) — —
Fatal major bleeding 7 (0.2) 1 (<0.1) — —
Other safety outcomes
Any cardiovascular event during treatment† 51 (1.3) 49 (1.2) — —
Any adverse event during treatment, excluding bleeding 2616 (65.4) 2607 (65.2) — —
Any serious adverse event during treatment, excluding 
bleeding
616 (15.4) 569 (14.2) — —
* Two-sided 95% confidence intervals for weighted relative risks were calculated with the use of asymptotic methods, 
with weights based on sample sizes per stratum of geographic region. The P values were calculated on the basis of the 
normal approximation. Outcomes for which relative risks and P values are not shown are those for which the analyses 
were not prespecified.
† Included are events of cardiovascular death, ischemic stroke, acute myocardial infarction, and acute stroke of unknown type.
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or renal failure, the presence of a central venous 
catheter, rheumatic disease, and cancer.15 The 
median age of the patients in MAGELLAN was 
71 years, and approximately 20% had impaired 
renal function (creatinine clearance less than 
50 ml per minute). In addition, just over 7% had 
active cancer (17% had a history of cancer), and 
approximately 4% had an acute inflammatory or 
rheumatic disease. There were no differences in 
characteristics between patients in the rivaroxaban 
group and those in the enoxaparin group that 
could explain the disparity in bleeding rates at 
day 10. However, the factors listed above, in com-
bination with the acute medical illness, could 
have contributed to the increased bleeding risk 
with extended thromboprophylaxis that was ob-
served in these patients as compared with pa-
tients undergoing major orthopedic surgery — a 
generally younger and healthier patient popula-
tion — among whom the benefits and safety of 
extended thromboprophylaxis have been well es-
tablished.9 The results of the current study sup-
port those from other studies that showed the 
efficacy of extended thromboprophylaxis11 but 
also the increased risk of bleeding.11,12
One limitation of our trial was the inclusion 
of asymptomatic proximal deep-vein thrombosis, 
as detected on ultrasonography, as part of the 
primary efficacy outcome. Ultrasonography is not 
performed routinely in medical patients.12 The 
use of this test may have influenced the trial in 
two ways. First, the performance of ultrasonog-
raphy at day 10 may have influenced the subse-
quent natural history of the disease because it 
may have resulted in the treatment of asymp-
tomatic disease. This could account for the risk 
reduction at day 35 that was lower than antici-
pated. In an analysis of the primary efficacy 
outcome events between day 11 and day 35, the 
relative risk reduction with extended-duration 
rivaroxaban was 35% (data not shown), which is 
closer to the expected 40%. Second, a substan-
tial subgroup of patients who underwent random-
ization could not be evaluated for the primary 
outcome because they did not undergo ultraso-
nography or because their ultrasonograms could 
not be properly assessed. The extent to which 
the lack of data for these patients may have in-
fluenced the findings of the trial is not clear.
In conclusion, we compared enoxaparin, at a 
dose of 40 mg once daily for 10 days, with rivarox-
aban, at a dose of 10 mg once daily for 35 days, 
for thromboprophylaxis in patients hospitalized 
with acute medical illness. The efficacy of stan-
dard-duration rivaroxaban was similar to that of 
enoxaparin, whereas the efficacy of extended-
duration rivaroxaban was superior to that of 
enoxaparin. However, rivaroxaban was associat-
ed with an increased risk of clinically relevant 
bleeding.
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